

10/501295
DT04 Rec'd PCT/PTO 12 JUL 2004

Appendix A

Claim Amendments

1. (Currently amended) Inclusion complex formed of element A and element B, wherein element A is chosen from pantoprazole, a solvate of pantoprazole, a hydrate of pantoprazole, a salt of pantoprazole with a base, a solvate of a salt of pantoprazole with a base, a hydrate of a salt of pantoprazole with a base, an enantiomer of pantoprazole, a solvate of an enantiomer of pantoprazole, a hydrate of an enantiomer of pantoprazole, [[or]] a salt of an enantiomer of pantoprazole, a solvate of a salt of an enantiomer of pantoprazole, a hydrate of a salt of an enantiomer of pantoprazole, or a mixture thereof; and wherein element B is chosen from cyclodextrin, a hydrate of cyclodextrin, a derivative of cyclodextrin or a mixture thereof.

2. (Currently amended) Inclusion complex according to claim 1 ~~formed of~~ wherein element A is chosen from pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium

sequihydrate, [[or]] pantoprazole magnesium dihydrate
or a mixture thereof.

3. (Currently amended) Inclusion complex according to claim 1 ~~or 2~~, wherein element B ~~the cyclodextrin~~ is β -cyclodextrin.
4. (Currently amended) Method of preparing preparation of an inclusion complex according to claim 1 comprising any ~~of claims 1 to 3~~ by reacting element A with element B ~~pantoprazole with the cyclodextrin~~ in a suitable solvent.
5. (Currently amended) Method according to claim 4, wherein the solvent is essentially ethanol.
6. (Currently amended) Inclusion complex prepared by the method obtainable according to claim 4.
7. (Currently amended) Inclusion complex according to claim 1, which is a 1/1 ~~(pantoprazole/cyclodextrin)~~ inclusion complex.
8. (Currently amended) Administration form comprising an

inclusion complex according to claim 1 any of claims 1
~~to 3~~ together with a suitable pharmaceutical
auxiliaries auxiliary.

9. (Canceled)

10. (Currently amended) Method of treating or preventing
a condition treatable or preventable with a pyridine-
2ylmethylsulfinyl-1H-benzimidazole, which comprises
administering to a subject prone to or afflicted with
a condition a pharmaceutically acceptable
administration form according to claim 8 comprising
[[an]] therapeutically effective amount of the
pantoprazole inclusion complex.

11. (New) Inclusion complex according to claim 2 wherein
element B is β -cyclodextrin.

12. (New) Method of preparing an inclusion complex
according to claim 1 comprising reacting element A
with element B in a suitable solvent.

13. (New) Method of preparing an inclusion complex
according to claim 3 comprising by reacting element A

with element B in a suitable solvent.

14. (New) Administration form comprising an inclusion complex according to claim 2 together with a suitable pharmaceutical auxiliary.

15. (New) Administration form comprising an inclusion complex according to claim 3 together with a suitable pharmaceutical auxiliary.